Protagenic Therapeutics, Inc.\new Accounts Payable and Accrued Liabilities
Protagenic Therapeutics, Inc.\new (PTIX) had Accounts Payable and Accrued Liabilities of $882.84 thousand as of 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Balance Sheet › Liabilities › Accounts Payable and Accrued Liabilities
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent · last filed 2023-05-15
- 2023-03-31: Accounts Payable and Accrued Liabilities $882.84K.
- 2022-12-31: Accounts Payable and Accrued Liabilities $775.63K.
- 2022-09-30: Accounts Payable and Accrued Liabilities $553.48K.
- 2022-06-30: Accounts Payable and Accrued Liabilities $463.09K.
| Period end | Accounts Payable and Accrued Liabilities |
|---|---|
| 2023-03-31 | $882.84K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $775.63K 10-Q · filed 2023-05-15 |
| 2022-09-30 | $553.48K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $463.09K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $783.64K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $799.53K 10-K · filed 2023-03-31 |
| 2020-12-31 | $571.52K 10-K · filed 2022-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |